Unternehmen wird geladen
Just reported
Q3 2026 results
From Edwards Lifesciences's results release of 4. November 2026; its quarterly report has since been filed.
Revenue
Actual
1,72B $
+10 % y/y
-1,5 % q/qGuided
1,67B $
midpoint
Above guide+2,7 %EPS, GAAP
Actual
0,53 $
+6,0 % y/y
+26 % q/qGuided
—
No guide given
Operating income, GAAP
Actual
299,1M $
-2,6 % y/y
-42 % q/qGuided
—
No guide given
Company outlook
Q4 2026
- Revenue1,67B $ – 1,75B $+8,9 % y/y First given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Edwards Lifesciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Medical Devices
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plc129,2B $A+
SYKStryker Corp.118,9B $A+
GEHCGE Healthcare Technologies Inc.37B $A
GKOSGlaukos Corp14,6B $A
PENPenumbra, Inc12,6B $A
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21. Okt. 2026CBGraded C, now B
MCKMckesson Corporation4. Nov. 2026BAGraded B, now A
CVSCVS Health Corp4. Nov. 2026BAGraded B, now A
BIIBBiogen Inc.28. Okt. 2026BAGraded B, now A- GEHCGE Healthcare Technologies Inc.28. Okt. 2026CAGraded C, now A
Womit das Unternehmen Geld verdient
- Catheter-delivered aortic valve replacement72 %
- Catheter-delivered mitral and tricuspid valve repair and replacement11 %
- Surgical heart valve products16 %
Die Umsatzanteile sind Schätzungen für nine months ended September 30, 2026 und keine Zahlen aus einem eingereichten Bericht.
Konkurriert mit
Was es verkauft5
SAPIEN
A family of tissue valves delivered through a catheter to replace a diseased aortic valve; some systems are also used for pulmonary valve replacement.
PASCAL
A catheter-delivered device that helps bring together the leaflets of a leaking mitral or tricuspid valve.
EVOQUE
A tissue valve delivered through a catheter to replace a leaking tricuspid valve.
2 weitere anzeigen
SAPIEN M3
A tissue valve delivered through a catheter to replace a diseased mitral valve.
INSPIRIS RESILIA, KONECT RESILIA, and MITRIS RESILIA
Surgical tissue valve products for aortic and mitral valve replacement; KONECT is a tissue valve conduit used in complex combined procedures.
Wer es kauft3
- Hospitals and health systems buy devices directly from Edwards sales teams or through distributors; in the United States, sales are mainly direct.
- Hospital purchasing groups and healthcare networks negotiate supplier contracts on behalf of hospitals.
- Heart specialists, including cardiac surgeons and interventional cardiologists, use the devices and take part in choosing treatments.
Worauf es steht, und was es umwerfen könnte
Wovon das Geschäft abhängt
- 1A large part of the business depends on hospitals adopting catheter-delivered aortic valve replacement and on clinicians choosing Edwards devices.
- 2Sales depend in part on government and private insurers covering procedures and paying hospitals enough to support their use.
- 3Some materials and components come from single-source suppliers; switching critical suppliers can require lengthy regulatory review.
- 4The company relies on clinical studies and regulatory clearances or approvals to bring devices to market and expand their permitted uses.
Was schiefgehen könnte
- 1If clinical studies do not show the needed results, or regulators do not approve new devices or uses, Edwards may be unable to sell those products or expand their use.
- 2Manufacturing, quality, safety, or delivery problems at Edwards or its suppliers could interrupt access to implanted heart valves and other devices.
- 3If insurers or government health programs restrict coverage or reduce payments, hospitals may buy fewer devices or seek lower prices.
Über Edwards Lifesciences Corporation
Edwards makes devices that replace or repair damaged heart valves. Some are delivered through a catheter, a thin tube passed through a blood vessel, while others are implanted during open-heart surgery. Hospitals and heart specialists use these devices to treat diseases affecting the aortic, mitral, and tricuspid valves.
- Hauptsitz
- Irvine, California, United States
- Gegründet
- 1958
- Beschäftigte
- Approximately 16,000 (December 31, 2025, medium)
- Notiert an
- New York Stock Exchange
- Geschäftsjahresende
- December 31
Gebaut aus den eigenen Einreichungen von Edwards Lifesciences Corporation bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.
